We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Hello again

25 September 2014 By Robert Cyran

The departure of the activist fund led by Jeff Ubben from the drug company’s board in May set off a slide in its stock, the currency critical to its M&A-machine strategy. ValueAct is rejoining, and may buy more. Some good investments are harder to leave than they are to make.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)